key: cord-0774977-9lax1n0r
authors: Flannery, Lisa E.; Kerr, Daniel M.; Hughes, Edel M.; Kelly, Colm; Costello, Jonathan; Thornton, Aoife M.; Humphrey, Rachel M.; Finn, David P.; Roche, Michelle
title: N-acylethanolamine regulation of TLR3-induced hyperthermia and neuroinflammatory gene expression: A role for PPARα
date: 2021-06-30
journal: J Neuroimmunol
DOI: 10.1016/j.jneuroim.2021.577654
sha: f5962fe8062241db78bd39a3171ab0ef279b8cf6
doc_id: 774977
cord_uid: 9lax1n0r

Increasing evidence suggests that SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is associated with increased risk of developing neurological or psychiatric conditions such as depression, anxiety or dementia. While the precise mechanism underlying this association is unknown, aberrant activation of toll-like receptor (TLR)3, a viral recognizing pattern recognition receptor, may play a key role. Synthetic cannabinoids and enhancing cannabinoid tone via inhibition of fatty acid amide hydrolase (FAAH) has been demonstrated to modulate TLR3-induced neuroimmune responses and associated sickness behaviour. However, the role of individual FAAH substrates, and the receptor mechanisms mediating these effects, are unknown. The present study examined the effects of intracerebral or systemic administration of the FAAH substrates N-oleoylethanolamide (OEA), N-palmitoylethanolamide (PEA) or the anandamide (AEA) analogue meth-AEA on hyperthermia and hypothalamic inflammatory gene expression following administration of the TLR3 agonist, and viral mimetic, poly I:C. The data demonstrate that meth-AEA does not alter TLR3-induced hyperthermia or hypothalamic inflammatory gene expression. In comparison, OEA and PEA attenuated the TLR3-induced hyperthermia, although only OEA attenuated the expression of hyperthermia-related genes (IL-1β, iNOS, COX2 and m-PGES) in the hypothalamus. OEA, but not PEA, attenuated TLR3-induced increases in the expression of all IRF- and NFκB-related genes examined in the hypothalamus, but not in the spleen. Antagonism of PPARα prevented the OEA-induced attenuation of IRF- and NFκB-related genes in the hypothalamus following TLR3 activation but did not significantly alter temperature. PPARα agonism did not alter TLR3-induced hyperthermia or hypothalamic inflammatory gene expression. These data indicate that OEA may be the primary FAAH substrate that modulates TLR3-induced neuroinflammation and hyperthermia, effects partially mediated by PPARα.

comparison, OEA and PEA attenuated the TLR3-induced hyperthermia, although only OEA attenuated the expression of hyperthermia-related genes iNOS, in the hypothalamus. OEA, but not PEA, attenuated TLR3-induced increases in the expression of all IRF-and NFκB-related genes examined in the hypothalamus, but not in the spleen. Antagonism of PPARα prevented the OEA-induced attenuation of IRF-and NFκBrelated genes in the hypothalamus following TLR3 activation but did not significantly alter temperature. PPARα agonism did not alter TLR3-induced hyperthermia or hypothalamic inflammatory gene expression. These data indicate that OEA may be the primary FAAH substrate that modulates TLR3-induced neuroinflammation and hyperthermia, effects partially mediated by PPARα. potential therapeutics limiting mast cell activation and inflammatory response to SARS-CoV-2 (Gigante et al., 2020; Lucaciu et al., 2021) . Recent data have indicated that the plantderived cannabinoid cannabidiol inhibits SARS-CoV-2 replication and viral gene expression, induces interferon (IFN) expression and up-regulates its antiviral signalling pathways (Nguyen et al., 2021) . Similarly, the synthetic cannabinoid agonist WIN55,212 has been shown to increase TLR3-induced IFN-β levels while attenuating pro-inflammatory NFκBrelated immune responses in astrocytes (Downer et al., 2011) . Increasing endogenous cannabinoid tone by inhibiting the catabolism enzymes for anandamide and 2-AG, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) respectively, has shown that FAAH, but not MAGL, inhibition attenuates TLR3-induced neuroinflammatory, but not peripheral, immune responses (Flannery et al., 2018a; Henry et al., 2014) . Furthermore, inhibition of TLR3-induced neuroinflammation following FAAH inhibition is associated with an attenuation of TLR3-associated hyperthermia, anxiety-like behaviour and enhanced nociceptive responding (Flannery et al., 2018b) , indicating that FAAH substrates are important modulators of TLR3-induced neuroinflammation and associated behavioural responding. In addition to the endocannabinoid anandamide, FAAH also metabolises the related fatty acid amides, N-oleoylethanolamide (OEA) and PEA (Cravatt et al., 1996) , and thus, inhibition of FAAH results in increases in all three substrates (Fegley et al., 2005; Flannery et al., 2018a) . It is unknown if one or all of these substrates is responsible for modulating the TLR3-induced neuroinflammatory and associated behavioural responding following FAAH inhibition.

The effects of AEA, OEA and PEA on TLR4-induced inflammatory responses have been well documented. AEA attenuates TLR4-induced production of pro-inflammatory cytokines and mediators such as TNF-α, IL-1β, prostaglandins (PG) and nitric oxide (NO) (Facchinetti et al., 2003; Molina-Holgado et al., 1997; Puffenbarger et al., 2000) , while concurrently increasing anti-inflammatory mediators such as IL-10 (Correa et al., 2010; Krishnan and Chatterjee, 2012) . N-acylethanolamine acid amidase (NAAA) is a further metabolic pathway for OEA and PEA, inhibition of which elicits potent immunosuppressive effects (Alhouayek et al., 2015; Piomelli et al., 2020; Skaper et al., 2015; Solorzano et al., 2009) . PEA reduces TLR4-induced increases in TNF-α production and IL-6 and iNOS expression in macrophages Solorzano et al., 2009 ) and inhibits TLR4-induced pro-inflammatory M1 microglia while augmenting anti-inflammatory M2a microglia (D'Aloia et al., 2021) . OEA decreased TLR4-induced increases in expression of pro-inflammatory cytokines iNOS and COX-2 in macrophages (Fan et al., 2014; Yang et al., 2016) . OEA and PEA induce antiinflammatory effects in a mouse model of colitis, directly via inhibition of TLR4-mediated immune responses (Esposito et al., 2014; Lama et al., 2020) . Within the brain, AEA modulates TLR4-induced inflammatory responses, temperature changes and hypophagia (Hollis et al., 2011; Steiner et al., 2011) . OEA and PEA attenuated TLR4-induced NFκB activity, IL-1β, COX-2, mPGES-1 expression and PGE2 levels in the hypothalamus, an effect associated with potentiation of TLR4-induced hypothermia (Sayd et al., 2015) . OEA blocks the TLR4-mediated increases in pro-inflammatory cytokines and chemokines, oxidative and nitrosative stress, and neurodegenerative cascades in frontal cortex of a rodent model of alcohol abuse (Orio et al., 2018; Rivera et al., 2019) and neuropsychiatric conditions (Moya et al., 2021) . Collectively, this demonstrates that AEA, OEA and PEA modulate TLR4induced inflammatory responses; however, there is a paucity of studies investigating the effects of individual N-acylethanolamines on TLR3-induced inflammatory responses. PEA has been shown to inhibit TLR3-induced increase in the expression and release of the chemokine MCP-1 in keratinocytes (Petrosino et al., 2010) . TLR3 plays a key role in the induction of the TMEV-model of multiple sclerosis, and FAAH inhibition, AEA and PEA has been shown to attenuate microglial activation, the expression of pro-inflammatory cytokines and ameliorates motor symptoms in this model (Mestre et al., 2005; Ortega-Gutierrez et al., 2005; Loria et al., 2008; Loria et al., 2010; Correa et al., 2011; Hernangomez et al., 2012) . However, effects of individual FAAH substrates on the acute TLR3-mediated neuroimmune responses and associated sickness behaviour has not been examined.

Enhancing Zhou et al., 2012) . As such, the role of PPARα on OEA-mediated modulation of TLR3induced hyperthermia and inflammatory gene expression was also examined.

J o u r n a l P r e -p r o o f 

Rats were randomly assigned to one of three treatment groups: Vehicle-Saline (n = 6), Vehicle-Poly I:C (n = 9), Methanandamide (meth-AEA)-Poly I:C (n = 10). Meth-AEA (20ug, Abcam, UK) or Vehicle (100% DMSO) were administered in a single acute i.c.v injection, in an injection volume of 4µl. This was followed 10 min later by an i.p, injection of poly I:C (3 mg/kg) or sterile saline (0.89% NaCl) administered in an injection volume of 1.5mg/kg. Due to the rapid metabolism of AEA in vivo, the stable AEA analogue meth-AEA was administered directly to the brain (i.c.v). The concentration of meth-AEA used was chosen based on previous literature demonstrating antinociceptive and gastroprotective effect when administered centrally (Garzon et al., 2009; Shujaa et al., 2009) . Core body temperature was measured using a rectal probe prior to any experimental manipulation and 4hrs post poly I:C/saline injection. Animals were sacrificed by decapitation at 4hrs post-poly I:C/saline administration, the hypothalamus excised, snap-frozen on dry ice and stored at -80 o C until assayed for expression of inflammatory mediators.

Rats were randomly assigned to one of four treatment groups: Vehicle-saline (n = 8),

Vehicle-poly I:C (n = 9), OEA-poly I:C (n = 9) and PEA-poly I:C (n = 9). OEA and PEA (20mg/kg, Abcam, UK) or Vehicle (ethanol: Cremophor: saline; 1:1:18) were administered i.p. in an injection volume of 2ml/kg followed 10 min later by an i.p, injection of poly I:C (3 mg/kg) or sterile saline (0.89% NaCl) administered in an injection volume of 1.5ml/kg. The dose of OEA was chosen as this has been shown to increase striatal levels of OEA from 15 min to 2 hrs post administration (Gonzalez-Aparicio et al., 2014; Plaza-Zabala et al., 2010) and pilot data in the lab demonstrated increased OEA concentration in the hypothalamus 1hr post administration. The dose of PEA was chosen based on published data demonstrating efficacy in reducing nociceptive behaviour (Pessina et al., 2015) . Temperature was recorded prior to injection and 4 hrs post poly I:C/saline administration. Animals were sacrificed by decapitation at 4hrs post-poly I:C/saline administration, the spleen and hypothalamus excised, snap-frozen on dry ice and stored at -80 o C until assayed for inflammatory gene expression.

Rats were randomly assigned to one of four treatment groups: Vehicle-Vehicle-saline (n = 8),

Vehicle-Vehicle-poly I:C (n = 9), Vehicle-OEA-poly I:C (n = 8), GW6471-OEA-poly I:C (n = 8) and GW6471-Vehicle-PEA-poly I:C (n = 7). OEA (20mg/kg, Abcam, UK) and GW6471

(2mg/kg) were dissolved in Vehicle (ethanol: cremophor: saline; 1:1:18) were administered i.p. in an injection volume of 2 ml/kg. GW6471 or Vehicle was administered 20 minutes prior to administration of OEA or vehicle followed 10 min later by an i.p, injection of poly I:C (3 mg/kg) or sterile saline (0.89% NaCl) in an injection volume of 1.5 ml/kg. The dose of GW6471 was chosen based on efficacy in reversing PEA-induced protective effects (Pessina et al., 2015; Scuderi et al., 2014) , without affecting nociceptive responding (Gaspar et al., 2020) or anxiety-like behaviour (unpublished in-house data). Temperature was recorded prior to injection and 4 hrs post poly I:C/saline administration, after which animals were sacrificed hypothalamus excised, snap-frozen on dry ice and stored at -80 o C until assayed for gene expression.

Rats were randomly assigned to one of three treatment groups: Vehicle-saline (n = 6), Vehicle-poly I:C (n = 8), Vehicle-WY14643 (n = 6). WY14643 (20mg/kg, Abcam, UK) was dissolved in Vehicle (10% DMSO) were administered i.p. in an injection volume of 2 ml/kg, followed 30 min later by an i.p, injection of poly I:C (3 mg/kg) or sterile saline (0.89% NaCl) J o u r n a l P r e -p r o o f in an injection volume of 1.5 ml/kg. The dose of WY14643 was chosen based on in vivo efficacy in several models (Lysne et al., 2019; Okine et al., 2015; Song et al., 2016) .

Temperature was recorded prior to injection and 4 hrs post poly I:C/saline administration, after which animals were sacrificed hypothalamus excised, snap-frozen on dry ice and stored at -80 o C until assayed for gene expression.

Intracerebroventricular (i.c.v.) guide cannulae were implanted into the rat brain as previously described (Henry et al., 2014) . In brief, under isoflurane anaesthesia (1-3% in O 2 ; 0.5L/min), a guide cannula (5mm, Plastics One Inc., Roanoke, Virginia, USA) was stereotaxically implanted into the right lateral ventricle (coordinates: AP: -0.07mm; ML: -0.15mm, DV: -0.30mm; (Paxinos, 2006) ). The cannula was permanently fixed to the skull using stainless steel screws and dental acrylic cement and the guide remained patent by the insertion of a stainless steel stylet (Plastics One Inc., USA). Animals received the broad spectrum antibiotic enrofloxacin (2.5mg/kg s.c.; Baytril, Bayer Ltd., Ireland) on the day of and for 3 days post surgery. Correct cannula placement was verified by the Angiotensin (Ang) II drinking test 3 days prior to the experiment. Animals were considered non-responders if they drank <3mls over 20 min post AngII infusion and were not included in the experiment. Over all experiments, the average number of non-responders was <5%. Animals were allowed to recover from surgery for at least 6 days prior to experimentation.

RT-qPCR was performed as previously described (Flannery et al., 2018a; Flannery et al., 2018b; Henry et al., 2014) . In brief, mRNA was isolated from hypothlamic tissue using NucleoSpin RNA II total RNA isolation kit (Macherey-Nagel, Germany) and reverse transcribed into cDNA using a High Capacity cDNA Archive kit (Applied Biosystems, UK).

Taqman gene expression assays (Applied Biosystems, UK) were used to quantify the gene of interest and real-time PCR was performed using an ABI Prism 7500 instrument (Applied Biosystems, UK. Assay IDs for the genes were as follows: IP-10 (Rn00594648_m1), IRF7 was calculated using the ∆∆CT method.

Data were analysed and graphs using Graph Pad Prizm v9. Normality and homogeneity of variance were assessed using Shapiro-Wilk and Levene's test, respectively. Data were analysed by One-Way ANOVA's followed by Student Newman Keules (SNK) post hoc analysis where appropriate. The level of significance was set at p < 0.05. Data are expressed as group means ± standard error of the mean (SEM).

The data revealed that poly I:C-induced an increase in temperature [F (2,19) (Fig 1a-d) . Meth-AEA (i.c.v.) did not alter poly I:C-induced hyperthermia or inflammatory gene expression in the hypothalamus (Fig 1a-d) .

The data revealed that poly I: confirmed that poly I:C-induced an increase in expression of SOCS1 and SOCS3, an effect attenuated by OEA, but not PEA (Fig 2j-k) 

In order to determine if the effect of OEA on inflammatory gene expression in the hypothalamus are due to modulation of peripheral immune responses following TLR3 activation, inflammatory gene expression was also examined in the spleen. (Fig 3) .

Several studies have demonstrated that anti-inflammatory effects of OEA have been attributed to activation of PPARα. Thus, the role of PPARα in mediating the effects of OEA on TLR3-induced hyperthermia and neuroinflammatory gene expression in the hypothalamus were examined in the current study. Analysis revealed that poly I:C-induced an increase in body temperature 4hrs post administration (P = 0.05), which was not observed in rats that received OEA and/or the PPARα antagonist GW6471 (Fig 4a) . hypothalamus, an effect not observed in rats pre-treated with OEA (Fig 4b-e) . Administration of GW6471 blocked the effects of OEA on inflammatory gene expression following poly I:C

administration. There was no significant effect of GW6471 alone on poly I:C-induced inflammatory gene expression in the hypothalamus (Fig 4b-e) .

In order to determine if the effects of OEA on TLR3-induced responses could be mimicked by PPARα agonism, the effects of systemic administration of the PPARα agonist WY14643

were examined. WY14643 did not alter TLR3-induced hyperthermia, IP-10 or TNFα expression in the hypothalamus (Fig 5) .

N-acylethanolamines exhibit potent anti-inflammatory effects, however, effects on viralmediated immune responses within the brain have not been extensively examined. The present study demonstrated that OEA and PEA, but not AEA, attenuate TLR3-induced hyperthermia and OEA attenuates the expression of IRF-and NFκB-related genes in the hypothalamus, including hyperthermic related genes (IL-1β, iNOS, COX2 and m-PGES).

Antagonism of PPARα prevented the OEA-induced attenuation of IRF-and NFκB-related genes in the hypothalamus following TLR3 activation, without altering temperature.

However, PPARα agonism did not alter TLR3-induced hyperthermia or hypothalamic inflammatory gene expression. While the mechanisms mediating the effects of PEA on TLR3-mediated hyperthermia remain to be determined, the data indicate that OEA attenuates TLR3-induced neuroinflammation and hyperthermia, an effect partially mediated by PPARα.

In line with previous data, (Cunningham et al., 2007; Flannery et al., 2018a; Henry et al., 2014; Murray et al., 2015) , the present study confirmed that poly I:C-induced activation of TLR3 elicits a robust induction of IFN-and NFκB-mediated immune responses both peripherally and centrally, accompanied by hyperthermia. Increasing FAAH substrate levels has been demonstrated to attenuate TLR3-induced hyperthermic and neuroinflammatory responses, effects specifically mediated at the level of the central nervous system (Flannery et al., 2018a; Flannery et al., 2018b; Henry et al., 2014) . The current data demonstrate that OEA and PEA, but not meth-AEA, attenuate TLR3-induced hyperthermia. In comparison, AEA, OEA and PEA have been shown to modulate TLR4-induced hypo- (Sayd et al., 2015; Steiner et al., 2011) or hyper-thermia (Hollis et al., 2011) , although no effect was observed when all OEA and PEA modulate the TLR4-induced hypothermic response, an effect associated with an attenuation in hypothalamic IL-1β, COX-2, mPGES-1 expression and PGE 2 levels (Sayd et al., 2015) . Similarly, the TLR3-induced hyperthermic response has been shown to be primarily mediated by the IL-1β-COX2 pathway (Fortier et al., 2004) . The current study demonstrated that OEA and PEA attenuates TLR3-induced hyperthermia; however, only Although PEA attenuated TLR3-induced hyperthermia, no effect was observed on the expression of inflammatory genes in the hypothalamus, suggesting differential mechanisms underlie the effects of OEA and PEA on TLR3-induced hyperthermia. We cannot rule out that PEA may have induced effects on hypothalamic inflammatory gene expression at an earlier timepoint than examined in this study. PEA has been reported to cross the blood brain barrier after an oral administration, although at very low concentrations (<1%) (Artamonov et al., 2005) and unpublished pilot data from our lab suggest that PEA levels were not elevated in the hypothalamus 1hr following administration. It should be noted that in addition to FAAH, OEA and PEA are also hydrolysed by NAAA, the inhibition of which has been shown to elicit potent immunosuppressive activity (Alhouayek et al., 2015; Piomelli et al., 2020; Skaper et al., 2015; Solorzano et al., 2009) . NAAA is highly expressed in cells of the immune system and thus, the lack of effect of PEA on hypothalamic gene expression may be due to low central tissue distribution due to its rapid metabolism by NAAA under inflammatory conditions. The effects of PEA on TLR3-induced hyperthermia is most likely mediated peripherally rather than at the level of the hypothalamus. However, the current study demonstrated that PEA did not alter the TLR3-induced increase in IFN-or NFκBrelated gene expression in the spleen, indicating that thermoregulatory effects are not merely due to global inhibition of peripheral immune responses to TLR3 activation. However, PEA may have altered the transcription or translation of these genes, the release of immune mediators or elicited effects in other tissues or organs. For example, it is possible that PEA may modulate peripheral, rather than central, PGE 2 levels. LPS and poly I:C dramatically increase the plasma level of PGE 2 60-90mins following administration, which in critical in the initiation of the hyperthermic response (Davidson et al., 2001; Rotondo et al., 1988) . In comparison, later phases of the hyperthermic response are mediated by PGE 2 produced by COX-2 and mPGES-1 in perivascular macrophages and endothelial cells in the brain (Steiner et al., 2006) . Therefore, by inhibiting poly I:C-induced increases in plasma levels of PGE 2, PEA may prevent the TLR3-induced hyperthermic response. It was not possible to assess this directly in the current study due to the time at which samples were taken (4hrs post poly I:C J o u r n a l P r e -p r o o f Journal Pre-proof administration). Alternatively, PEA may mediate its effects by modulating cardiovascular or metabolic pathways (Karimian Azari et al., 2020; Mattace Raso et al., 2014) involved in thermoregulation. Further studies will be required to examine the mechanisms by which PEA is mediating its inhibitory effects on the poly I:C-induced fever response.

Overall, the data herein demonstrate that the FAAH substrate OEA elicits potent neuroimmuno-regulatory effects partially mediated by PPARα, which limit the hyperthermic response to TLR3 activation following viral infection. These effects mimic those observed following FAAH inhibition, and as such, OEA may be the primary FAAH substrate mediating protective effects on TLR3-induced neuroinflammation, sickness behaviour and long-term psychiatric and neurological changes. Data expressed as mean ± SEM (n = 6-8 per group). *** p < 0.001 **p < 0.01 *p < 0.05 vs vehicle-saline. 

Highlights  meth-AEA does not alter TLR3-induced hyperthermia or hypothalamic inflammatory gene expression  OEA and PEA attenuates TLR3-induced hyperthermia  OEA, but not PEA, attenuates TLR3-induced increases in hypothalamic IRF-and NFκB-related gene expression  PPARα antagonism prevents OEA-induced attenuation of hypothalamic IRF-and NFκBrelated gene expression following TLR3 activation  OEA likely the primary FAAH substrate that modulates TLR3-induced neuroinflammation and hyperthermia, effects partially mediated by PPARα 

The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism

Endogenous cannabinoids induce fever through the activation of CB1 receptors

Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats

Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine

Pharmacological Blockade of PPAR Isoforms Increases Conditioned Fear Responding in the Presence of Nociceptive Tone

Poly I:Cinduced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression

Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19

The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism

Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and

FAAH-mediated modulation of TLR3-induced neuroinflammation in the rat hippocampus

For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders

Pharmacological inhibition of FAAH modulates TLR-induced neuroinflammation, but not sickness behaviour: An effect partially mediated by central TRPV1

The endocannabinoid arachidonylethanolamide attenuates aspects of lipopolysaccharide-induced changes in energy intake, energy expenditure and hypothalamic Fos expression

Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health

Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation

The anti-inflammatory and immune-modulatory effects of OEA limit DSS-induced colitis in mice

Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as antiinflammatory compounds

The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide

quest of a new therapeutic approach in COVID-19: the endocannabinoid system

Short-term treatment with a peroxisome proliferator-activated J o u r n a l P r e -p r o o f Journal Pre-proof receptor alpha agonist influences plasma one-carbon metabolites and B-vitamin status in rats

Does COVID-19 contribute to development of neurological disease?

Palmitoylethanolamide in CNS health and disease

Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes

Cerebellar and cortical TLR4 activation and behavioral impairments in Wernicke-Korsakoff Syndrome: Pharmacological effects of oleoylethanolamide

Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C

Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response

Systemic administration of WY-14643, a selective synthetic agonist of peroxisome proliferator activator receptoralpha, alters spinal neuronal firing in a rodent model of neuropathic pain

The rat Brain in Stereotaxic Coordinates

Protective effect of palmitoylethanolamide in a rat model of cystitis

Protective role of palmitoylethanolamide in contact allergic dermatitis

N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition

Effects of the endogenous PPAR-α agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice

Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells

The Basal Pharmacology of Palmitoylethanolamide

Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum

Pyrogenic immunomodulators increase the level of prostaglandin E2 in the blood simultaneously with the onset of fever

Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases

Systemic Administration of Oleoylethanolamide Protects J o u r n a l P r e -p r o o f Journal Pre-proof from Neuroinflammation and Anhedonia Induced by LPS in Rats

Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease

Analysis of the effect of neuropeptides and cannabinoids in gastric mucosal defense initiated centrally in the rat

N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution

Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation

Peroxisome Proliferator-Activated Receptor alpha Activation against Cardiac Ischemia-Reperfusion Injury Is Related to Upregulation of Uncoupling Protein-3

Cellular and molecular bases of the initiation of fever

The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors

Effects of cannabinoids and their receptors on viral infections

Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA

Increased expression of toll-like receptor 3, an anti-viral signaling molecule, and related genes in Alzheimer's disease brains

N-Oleoylethanolamine Reduces Inflammatory Cytokines and Adhesion Molecules in TNF-alpha-induced Human Umbilical Vein Endothelial Cells by Activating CB2 and PPAR-alpha

Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPARalpha signaling and inhibiting the NF-kappaB and ERK1/2/AP

Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor alpha

Figure 1: The effect of meth-AEA (i.c.v.) on poly I:C induced (a) hyperthermia and increases in (b) IP-10, (c) TNF-α and (d) IL-1β expression in the hypothalamus, 4hrs post poly I:C administration. Data expressed as mean ± SEM (n = 5-9 per group

01 vs vehicle-saline-treated counterparts

Figure 2: The effect of OEA or PEA on poly I:C induced (a) hyperthermia and increases in inflammatory gene expression of (b) IP-10, (c) IRF7, (d) TNF-α, (e) IL-1β, (f) IL-10, (g) iNOS, (h) COX2, (i) MPGES, (j) SOCS1 and (k) SOCS3 in the hypothalamus, 4hrs post poly I:C administration. Data expressed as mean ± SEM

The authors would like to gratefully acknowledge funding received from the Science